Cardiff Oncology, Inc. (CRDF) Total Return Calculator with Dividends Reinvested

Cardiff Oncology, Inc.

Popular:

The total return for Cardiff Oncology, Inc. (CRDF) stock is -59.37% over the past 12 months. So far it's down 42.11% this year. The 5-year total return is -81.33%, meaning $10,000 invested in CRDF stock 5 years ago would be worth $1,867 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CRDF 1 year ago, it would be worth $4,063 today — you'd have lost $5,937.

With Dividends Reinvested$4,063-59.37%

Price Only (No DRIP)$4,063-59.37%

Period2025-06-12 → 2026-06-12

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CRDF

1Y$4,063-$5,937 (-59.4%)-59.4% CAGR

3Y$9,506-$494 (-4.9%)-1.7% CAGR

5Y$1,867-$8,133 (-81.3%)-28.5% CAGR

10Y$52-$9,948 (-99.5%)-41.0% CAGR

15Y$223-$9,777 (-97.8%)-22.4% CAGR

20Y$22-$9,978 (-99.8%)-26.3% CAGR

30Y$10-$9,990 (-99.9%)-20.7% CAGR

Cardiff Oncology, Inc. did not pay dividends during this period. Total return = price return.

Loading CRDF total return...

As of 2026-06-12

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-42.11%	—	-42.11%	—	$5,789
1Y	-59.37%	-59.37%	-59.37%	—	$4,063
3Y	-4.94%	-1.67%	-4.94%	—	$9,506
5Y	-81.33%	-28.52%	-81.33%	—	$1,867
10Y	-99.48%	-40.95%	-99.48%	—	$52
15Y	-97.77%	-22.40%	-97.77%	—	$223
20Y	-99.78%	-26.31%	-99.78%	—	$22
30Y	-99.90%	-20.70%	-99.90%	—	$10

Risk & Highlights

Best Year+1339.20%2020

Worst Year-85.75%2018

Max Drawdown-68.54%2025-07-17 → 2026-06-03

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-27.07%	-27.07%	—	+0.41%	-27.5pp
2025	-34.04%	-34.04%	—	+16.64%	-50.7pp
2024	+183.66%	+183.66%	—	+24.00%	+159.7pp
2023	+0.00%	+0.00%	—	+24.81%	-24.8pp
2022	-78.23%	-78.23%	—	-19.95%	-58.3pp

CRDF underperformed the S&P 500 by 82.22pp over the past year (-59.37% vs +22.86%).

Loading summary...

CRDF Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CRDFCardiff Oncology, Inc.	$105M	-6.1%	-42.1%	-59.4%	—	-4.9%	-81.3%	-99.5%
TGTXTG Therapeutics, Inc.	$7.6B	+16.4%	+69.1%	+32.5%	—	+89.0%	+29.3%	+605.4%
MGNXMacroGenics, Inc.	$252M	+12.5%	+146.0%	+155.5%	—	-31.5%	-81.0%	-85.0%
NKTRNektar Therapeutics	$1.2B	-24.3%	+36.8%	+577.9%	—	+594.5%	-77.6%	-73.6%
IMVTImmunovant, Inc.	$6.9B	+17.3%	+29.8%	+110.9%	—	+55.0%	+213.0%	+237.9%
KPTIKaryopharm Therapeutics Inc.	$81M	+6.6%	+32.1%	+117.9%	—	-70.1%	-93.9%	-92.4%
AGIOAgios Pharmaceuticals, Inc.	$1.8B	+3.7%	+8.4%	-14.6%	—	+13.0%	-49.4%	-43.3%
AGENAgenus Inc.	$137M	-4.1%	+2.2%	-31.5%	—	-91.8%	-96.8%	-95.9%
FATEFate Therapeutics, Inc.	$240M	-8.4%	+108.1%	+47.1%	—	-61.9%	-97.7%	+15.7%
PRMEPrime Medicine, Inc.	$501M	-16.0%	-21.4%	+90.1%	—	-81.1%	-81.9%	-57.7%
RVMDRevolution Medicines, Inc.	$32.7B	+5.6%	+94.7%	+274.3%	—	+507.9%	+345.1%	+432.4%

Compare:CRDF vs TGTX CRDF vs MGNX CRDF vs NKTR CRDF vs TGTX vs MGNX

About CRDF Dividend Returns

Cardiff Oncology, Inc. (CRDF) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CRDF over the past year?

Cardiff Oncology, Inc. (CRDF) delivered a return of -59.37% over the past year. Since CRDF does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CRDF be worth today?

A $10,000 investment in Cardiff Oncology, Inc. one year ago would be worth $4,063 today, representing a loss of $5,937.

Q3Does CRDF pay dividends?

Cardiff Oncology, Inc. (CRDF) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CRDF, the total return equals the price-only return.

Q4Did CRDF beat the S&P 500?

No, Cardiff Oncology, Inc. (CRDF) underperformed the S&P 500 by 82.22 percentage points over the past year. CRDF delivered a total return of -59.37%, compared to the S&P 500's 22.86%. This means a passive S&P 500 index fund outperformed CRDF by 82.22pp during this period.

Q5What is CRDF's worst drawdown?

Cardiff Oncology, Inc. (CRDF) experienced a maximum drawdown of -68.54% over the past year, declining from its peak on 2025-07-17 to its trough on 2026-06-03. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CRDF's long-term total return over 10, 20, or 30 years?

Here are Cardiff Oncology, Inc. (CRDF)'s long-term returns with dividends reinvested. Over 10 years, the total return is -99.5% (-41.0% CAGR) — $10,000 would have grown to $52. Over 20 years: -99.8% total return (-26.3% CAGR) — $10,000 → $22. Over 30 years: -99.9% total return (-20.7% CAGR) — $10,000 → $10. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CRDF's best and worst year?

Cardiff Oncology, Inc.'s best calendar year was 2020 with a total return of 1339.2%. Its worst year was 2018 with a total return of -85.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 1425.0 percentage points.

How much would $100/month in CRDF be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →